Enfusion — Investor Day (March 2024)
50 slides from Enfusion's investor day presentation, Mar 19, 2024
Slide 1: Investor & Analyst Day 2024
Investor & Analyst Day 2024
Slide 2: Forward-looking statements
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 2 Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities
Slide 3: Enfusion: Our Time is Now
Enfusion: Our Time is Now Oleg Movchan Chief Executive Officer
Slide 4: Our Journey for the Day
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. Client Fireside Chat Key Points & Closing Remarks Measuring Success: Revenue & Margin Trajectory Go-to-Market Strategy Total Addressable Market Analysis & Product Strategy Enfusion’s Value Proposition Enfusion: Our Time is Now 4 Our Journey for the Da
Slide 5: PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 5
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 5
Slide 6: Enfusion's Innovation Timeline
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 6 Enfusion’s Innovation Timeline PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 6 Enfusion’s Innovation Timeline
Slide 7: Revenue by Region
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. RIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 7 Revenue by Region Americas EMEA APAC 21% 11% 68% 2020 15% 23% 62% 2023 Enfusion’s Geographic Client Footprint 20+ countries, territories and regions
Slide 8: Macro Trends Support & Enhance Our Value Proposition
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 8 Macro Trends Support & Enhance Our Value Proposition Enfusion’s Value Proposition Active Management Fee Compression Electronification of Markets Macro Market Trends SaaS Eating Enterprise Models Rising Costs as Share of Revenue
Slide 9: Enormous Upside Potential: $25B TAM
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 9 It is our time to disrupt the traditional asset management segment the same way we disrupted the alternatives segment Enormous Upside Potential: $25B TAM $25B $15.3B $1.2B $1.3B $7.2B Private Equity & Private Credit Firms Equity Hedge Funds Non-Equi
Slide 10: Enfusion is a Unique Collaboration Platform
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. Compliance Trading Risk Operations Investor Relations Business Development Portfolio Managers Research Enfusion is a Unique Collaboration Platform Our SaaS architecture & product roadmap expand collabor
Slide 11: Enfusion's World Class Team
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. RIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. Enfusion’s World Class Team Oleg Movchan Chief Executive Officer Neal Pawar Chief Operating Officer Bronwen Bastone Chief People Officer Brad Herring Chief F
Slide 12: Enfusion's Value Proposition
Enfusion’s Value Proposition Neal Pawar Chief Operating Officer
Slide 13: The Perfect Storm: Why Enfusion is Positioned to Win
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 13 The Perfect Storm: Why Enfusion is Positioned to Win Built SaaS-Native from day one Enfusion’s History Trailblazing technology foundational to future growth Client’s Race to Cloud & Scalability Client’s Time-to-Market Pressures Macro Market Trends
Slide 14: How SaaS-Native Lowers Client's Total Cost of Ownership
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. How SaaS-Native Lowers Client’s Total Cost of Ownership (TCO) SaaS-Native all-in TCO can be ~ the price compared to a legacy, on-prem provider Cost for the client 100% 33% + + Excluded from client TCO ALL-In TCO for Clients Client’s Total Cost + + On
Slide 15: Enfusion's Core Designed for Scale, Flexibility & Cost
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 15 Enfusion’s Core Designed for Scale, Flexibility & Cost Enables clients to rapidly migrate from patchwork systems to a single platform that scales predictably. Enfusion’s Core What it brings to the client Multi-tenant SaaS Lower TCO, rapid onboardin
Slide 16: 2018: Enfusion Solves Key Front & Middle Office Aspects
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 16 2018: Enfusion Solves Key Front & Middle Office Aspects of the Investment Process OEMS & Compliance Portfolio Management Solutions Portfolio Construction Workbench Decision Analytics Data Platform Portfolio Analytics Reference Data Book of Record I
Slide 17: 2024: Enfusion's Evolution Addresses Full Investment Process Needs
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. PROPRIE 17 OEMS & Compliance Portfolio Management Solutions Portfolio Construction Workbench Decision Analytics Data Platform Portfolio Analytics Reporting Reference Data Book of Record Managed Services 2024: Enfusion’s Evolution Addresses Full Invest
Slide 18: Expanded Functionality Allowed Enfusion to Move Upstream
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. Expanded Functionality Allowed Enfusion to Move Upstream 18 2018 2023 1 22 21 4 Traditional Asset Managers & Asset Owners Non-Equity Hedge Funds 5clients generating $500K+ ARR clients generating $500K+ ARR Non-Equity Hedge Funds Equity Hedge Funds 51
Slide 19: PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 19
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 19
Slide 20: Q&A
Q&A
Slide 21: Total Addressable Market Analysis & Product Strategy
Total Addressable Market Analysis & Product Strategy Brad LeClair Head of Product
Slide 22: Enfusion: Expanding TAM Serviceability
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 22 Enfusion: Expanding TAM Serviceability Serviceable Addressable Market (SAM) is built up from a bottoms-up approach $15.3B $8.8B 0.2% $1.2B $700M 6.4% $1.3B $1B 5.3% $7.2B TAM SAM Captured % of TAM Traditional Asset Managers & Asset Owners Equity He
Slide 23: Proven Track Record of Product-Led Approach
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. PROPRIETARY ©2024 E NFUSION. ALL RIGHTS RESERVED. Commodities Year-end 2020 Year-end 2023 TAM SAM Captured % of TAM $1.3B $1B 5.3% Non-Equity Credit Hedge Funds Global Macro Equity Hybrid Multi Manager Event Driven Multi Strategy Commodities 244% Cred
Slide 24: Wisdom of Crowds: Broad Client Base Validates Our Product
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 24 “Wisdom of Crowds:” Broad Client Base Validates Our Product Growth & Maturation Enfusion will again drive a product-led approach to achieve product market fit in Traditional Asset Managers & Asset Owners Front-to-Back 50% Traditional Asset Managers
Slide 25: Enfusion's Product Strategy
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 25 Desktop & Tooling for Investment Decision Makers + User-Centric Modern Design & Workflow Richer Data Analytics & Insights Democratizing Data Access Investing in Product & Engineering Teams Radical Cl
Slide 26: Q&A
Q&A
Slide 27: Go-to-Market Strategy: Product Led Strategy and Client Evangelism
Go-to-Market Strategy: Product Led Strategy and Client Evangelism Dan Jacobs Chief Revenue Officer
Slide 28: Our Winning Formula Applied to Traditional Asset Managers
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. Features and workflows vary by investment product and trading strategy… but Enfusion’s value proposition is universal to all investment managers 28 Our Winning Formula Applied to Traditional Asset Managers Investment Process Clarity Business Transform
Slide 29: GTM Position: Market Leading Solution for Hedge Funds
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 29 GTM Position: Market Leading Solution for Hedge Funds and Disruptive Choice for Traditional Asset Managers Hedge Funds 1 MARKETING STRATEGY Elevate Brand Accelerate Brand Awareness GO-TO-MARKET (GTM) Land and Expand Harness Enfusion Community Unloc
Slide 30: Growing the Relationship: Three Avenues to Increase Revenue
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. PROPRIETARY©2024 ENFUSION. ALL RIGHTSRESERVED. Organic Client Growth (e.g. Increased AUM, new users, etc...) Product & Service Upsell (e.g. Additional solutions for existing users) Business Unit Expansion (e.g. Expand to more areas within a larger org
Slide 31: The Enfusion Expansion Story: Sell Local, Think Global
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. RIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. The Enfusion Expansion Story: Sell Local, Think Global Sales org diversified from generalists to a global team of specialists, well versed in local requireme
Slide 32: SaaS-Native Edge Shortening Onboarding Cycles
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 32 SaaS-Native Edge Shortening Onboarding Cycles While an expanded footprint with traditional asset managers can lengthen average sales & onboarding cycles, Enfusion’s ability to implement efficiently is a competitive advantage 4 Months Hedge Funds 8
Slide 33: Q&A
Q&A
Slide 34: Fireside Chat: Sculptor Capital Management & PanAgora Asset Management
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 34 Fireside Chat: Sculptor Capital Management & PanAgora Asset Management Lotte Tønsberg EMEA Head of Sales Srinivas Vasantharajan Chief Information Officer Will Pearce Senior Trader
Slide 35: Financial: Revenue & Margin Trajectory
Financial: Revenue & Margin Trajectory Brad Herring Chief Financial Officer
Slide 36: 2024 Guidance
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 36 2024 Guidance GAAP Revenues $200-210 million $40-45 million 50-55% Adjusted EBITDA FCF Conversion
Slide 37: Medium Term Guide (2025-2027)
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 37 Medium Term Guide (2025-2027) Annual Revenue Growth 20-22% 200-400 bps 300-500 bps Annual Adj EBITDA Margin Expansion Annual FCF Conversion Expansion
Slide 38: Revenue Growth
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 38 Revenue Growth Growth generated by new and existing clients $112 $80 $200-210 2024 (E) $175 2023 $150 2020 2021 2022 + 250% in 4 years Onboarding of new logos: “Front Book” Growth from our existing customer base: “Back Book” Enfusion revenues grow
Slide 39: Typical Client Revenue Journey
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 39 Typical Client Revenue Journey Smaller/Simple Client Year 1 On-boarding/Organic Growth Year 2 Organic Growth Included in NDR Realization of Booking Expectation Larger/Complex Client Year 1 On-boarding/Ramping Year 2 Ramping/Organic Growth Front Boo
Slide 40: Components of Revenue Growth
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 40 Components of Revenue Growth Revenue growth is forecast to accelerate to 20+% into the medium term 40% 35% 16% (Midpoint) (Midpoint) 2021 2022 2023 2024 (E) Medium Term (E) 30% 10% 3-5% 12-15% 4-6% 14-18% 29% 6% -2% 18% 18% 21% Front Book Back Book
Slide 41: Front Book Growth Factors
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 41 Front Book Growth Factors Signing more and larger clients equates to mid-teens growth from the front book Blended CAGR = 11% 2020 2021 2022 2023 2024 (E) 2025 (E) 2026 (E) Count of New Client Adds ACV of New Client Adds 2020 2021 2022 2023 2024 (E)
Slide 42: Back Book Growth Drivers
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 42 Back Book Growth Drivers Back Book contributes mid-single digits of annual revenue growth 13% 10% 6% -2% (Midpoint) (Midpoint) -3% 10% 3% 7-10% 8-11% -(4-5)% -4% -6% 2021 2022 2023 2024 (E) Medium Term (E) 4% 5% -(4-5)% Net Organic Growth Churn Net
Slide 43: Evolution of Client ARR Distribution and ACV
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 43 Evolution of Client ARR Distribution and ACV Client Book continues to evolve toward larger ACV clients 59% 24% 55% 25% 32% 46% 30% 43% 2020 2021 2022 2023 2024 E 2025 E 2026 E 17% 20% 22% 27% 28% 39% 33% 28% 37% 35% $172 $184 $207 $219 29% 41% 30%
Slide 44: Anticipated Drivers of Annual Margin Expansion
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 44 Anticipated Drivers of Annual Margin Expansion Margins are forecast to expand annually including investments to support growth 6-8% 3. Investments in Product and Technology 2. Operational efficiencies 4. Investments in Sales and Distribution 1. Sca
Slide 45: Dilution and Stock Based Compensation (SBC)
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 45 Dilution and Stock Based Compensation (SBC) 2022 2023 2024 (E) Medium Term (E) 1.0% -3.9% 2.0-2.5% 2.0-3.0% Annual Dilution from Incentive Programs (Annual issuances / BoP Fully Diluted Shares Outstanding) Annual Stock Based Compensation ($M) Weigh
Slide 46: Q&A
Q&A
Slide 47: Closing Remarks
Closing Remarks Oleg Movchan Chief Executive Officer
Slide 48: Our Time is Now
PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 48 Our Time is Now Creating shareholder value by executing on our mission All Workflows Durable Financial Profile Relentless Innovation World Class Team Enfusion’s Mission We deliver exceptional tech enabled client experience Leverage our massive clie
Slide 49: Q&A
Q&A
Slide 50: Thank you
Thank you